Form 8-K - Current report:
SEC Accession No. 0001193125-24-214188
Filing Date
2024-09-05
Accepted
2024-09-05 16:06:55
Documents
13
Period of Report
2024-09-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d857897d8k.htm   iXBRL 8-K 23648
  Complete submission text file 0001193125-24-214188.txt   148602

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA algs-20240903.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20240903_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20240903_pre.xml EX-101.PRE 11696
15 EXTRACTED XBRL INSTANCE DOCUMENT d857897d8k_htm.xml XML 3780
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 241281447
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)